SecBot SecBot
8-K ·Filed Nov 12, 2026

RVPH

REVIVA PHARMACEUTICALS HOLDINGS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed4d 7h ago SEC0001437749-26-036647
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

FDA feedback on the new brilaroxazine formulation, expected in Q4 2026, is the next major catalyst. The company's ability to secure additional financing will determine whether RECOVER-2 enrollment can begin in 1H 2027. Monitor for any partnership announcements that could extend cash runway.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

RVPH drug pipeline →

brilaroxazine

◆ Mixed Named in this 8-K
Impact
Phase
Phase 3
Time to market
If approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
Next catalyst
None dated

What to watchThe immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.

Price Chart

Loading chart...

Executive Summary

Reviva reported Q3 2026 net loss of $2.3M ($0.17 per share), narrower than the $4.0M loss in Q3 2025. Cash stood at $17.5M. The company expects FDA feedback in Q4 2026 on a new brilaroxazine formulation, with RECOVER-2 Phase 3 enrollment contingent on additional financing. The stock trades on OTCQB after Nasdaq delisting.

Key Financial Metrics

EPS
−$0.17
est −$0.18 · +5.6%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Net loss of $2.3M ($0.17 per share) for Q3 2026, vs $4.0M ($1.09) in Q3 2025
  • Cash and cash equivalents of $17.5M as of September 30, 2026
  • FDA feedback on new brilaroxazine formulation expected Q4 2026
  • RECOVER-2 Phase 3 enrollment expected 1H 2027, subject to additional financing
  • U.S. patent office granted priority examination (Track 1) for new formulation patent
  • Company anticipates filing for Nasdaq relisting in 1H 2027
  • Common stock currently quoted on OTCQB after Nasdaq delisting

Financial Impact

Q3 2026 net loss $2.3M vs $4.0M in Q3 2025; cash burn rate ~$1.5M per quarter

net losscash positionoperating expenses

Risk Factors

  • Nasdaq delisting completed; OTCQB trading may reduce liquidity and access to capital
  • RECOVER-2 enrollment contingent on additional financing; cash runway may be insufficient
  • No revenue; pre-commercial stage with no approved products
  • FDA feedback on new formulation could delay or alter clinical development path

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-036647
Document: 0001437749-26-036647-index-headers.html0001437749-26-036647
Document: 0001437749-26-036647-index.html0001437749-26-036647
Document: 0001437749-26-036647.txt0001437749-26-036647
8-K Data (Synthetic)0001437749-26-036647

Track record

12 reports on RVPH

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 Viewing No price data
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3533 Now $0.3504 −0.81% settles Feb 11
  3. Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
  4. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
  5. Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
  6. May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
  7. May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
  8. Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
  9. Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
  10. Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 5h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026